• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Windtree Therapeutics prices $20m offering

Windtree Therapeutics prices $20m offering

May 20, 2020 By Sean Whooley

Windtree TherapeuticsWindtree Therapeutics (OTCQB:WINT) announced today that it priced a public offering of common stock worth approximately $20 million.

The Warrington, Pa.-based company’s offering includes more than 2.7 million units of common stock at $7.25 per unit. Each unit consists of one share of common stock and one warrant to purchase one share of common stock at an exercise price of $7.975 per share, according to a news release.

Windtree’s warrants are exercisable for five years from the date of issuance and will be issued separately, with the company expecting gross proceeds of $20 million. Windtree intends to use the proceeds to advance its study of the KL4 surfactant for treating COVID-19-related lung injury, as well as for istaroxime Phase 2 start-up activities, the clinical development of Aerosurf for respiratory distress syndrome, pre-clinical studies of its oral SERCA2a activators for business development and other general purposes.

The company is also granting underwriters a 45-day option to purchase up to 413,793 additional shares of common stock and/or warrants to purchase up to 413,793 additional shares, or any combination of the two. Windtree expects the offering to close on May 22.

Ladenburg Thalmann & Co. Inc. is acting as sole book-running manager for the offering. National Securities Corporation is acting as the lead manager for the offering.

In connection with the offering, Windtree said its common stock has been approved for listing on the Nasdaq Capital Market. It began trading under the symbol “WINT” today.

Filed Under: Business/Financial News, Cardiovascular, Clinical Trials, Funding Roundup, Respiratory, Wall Street Beat Tagged With: Windtree Therapeutics

More recent news

  • Medtronic reports first patient treated in study of multi-organ denervation for hypertension
  • Baxter turns to an automation company for its new CEO
  • Pristine Surgical appoints new CFO
  • Boston Scientific wins expanded FDA nod for Farapulse PFA
  • FDA warns on issue with J&J Abiomed pump controllers related to 3 deaths

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy